Primary Care Skin Cancer referrals

(Suspicious & Non-healing skin lesions)

Atopic Dermatitis

Psoriasis

Dr Taha Aldeen

Consultant Dermatologist

Barnsley Hospital, Barnsley S75 2EP

26/02/2015

Disclosure

www.google.com

www.bad.org.uk

www.pubmed.com

Skin pigment

Ethnicity vs skin cancer

Skin melanosomes within keratinocytes

Protect from sun damage

Determine skin colour




BLACK
BROWN
GRAY
BLUE
Stratum corneum
Epidermis
Dermis

Sun radiation

Visible 48% 400-700 nanometers (nm)

Infrared 46% >700 nm

Ultraviolet (UVL) 6% & invisible to the human eye, but can damage skin DNA. Divided into UVA, UVB & UVC.

UVA 320-400 nm (90% of UVL) long wavelength → penetrates ozone, window glass, dermis → tanning (sun beds), aging, cancer, but no burns

UVA subdivided into UVA-2 320-340 nm & UVA-1 340-400 nm

UVB 290-320 nm largely blocked by ozone, only penetrates epidermis, stronger in mid day (10am-4pm) & summer → sun burn & cancer

UVC <290 nm & completely blocked by ozone

Fitzpatrick Skin types:

Type I: always burns, never tan

Type II: burns easily, tan with difficulty

Type III: burns moderately, tan gradually

Type IV: burn minimally, tan well

Type V: rarely burns, tan easily

Type VI: never burns, deeply pigmented



Prevention:

SPF ≥ 30 (times to have skin burn), but need to apply a tea spoon for the face & re-apply every 2h, and it only blocks UVB & not UVA which can also cause skin cancer. So use SPF with UVA blocking cream

Senesce cream is a SPF used for sensitive skin

Vitamin D is synthesized in the skin by UVB exposure or obtained from diet/drug supplement.

There are many studies reported an association between vitamin D deficiency and cancer, melanoma, psoriasis, eczema ....but no evidence available yet to prove the causative link.

Vitamin D3 oral supplement can be give for people with low Vitamin D level.

Melanocytic Melanoma (MM) ? A suspicious skin lesion

In 2011, the 5th most common cancer in the UK, 13,348 new cases reported





A- Asymmetry - ½ of the pigmented lesion is not similar to other ½

B- Border -Irregular borders

C- colours- Multiple colours

D- Diameter - > 6mm

E- Evolution - Changing in colour, size, shape, or become symptomatic e.g. Itchy or bleed

Risk factors: Caucasian skin (type I, II, III), intense intermittent (not persistent) sun exposure, childhood blistering sun burn, genetic (BRAF +ve in 50% of the cases), dysplastic naevus, >50 moles present, a new mole suddenly appear(around 80% arise from normal skin & 20 % arise from previous normal or dysplastic naevus), Melanoma in situ (MIS), immune suppressed, HIV, giant hairy naevus, rare genetic disorders e.g. XP

MM types: Superficial (70%), nodular, acral lentiginous m (palm, sole, subungual), lentigo maligna m, amelanotic m, mucosal, retina, genital & occult m.

Differ. Diagnosis: seborrheic keratosis (seb. warts), pigmented BCC, dysplastic n, MIS, solar lentigo (liver spots), blue n, lichenoid AK, dermatofibroma, Spitz's n, angiomas

Management: (excision & skin cancer MDT review)

Diagnosis: always excisional biopsy (unless large lesion) with 2mm margin, LDH and oncology referral for thick melanoma

Melanoma in situ (lentigo maligna) with no regression treated by 5 mm wide local excision (WLE) of the scar & no follow-up (FU) unless the patient has atypical moles.

Stage IA Breslow < 1 mm, no ulceration, mitoses < 1 mm (5y survival >90%) > 1-2 cm WLE & FU for 1 year (y).

Stage IB Breslow < 1 mm, with ulceration or mitoses ≥1 mm or 1–2 mm, no ulceration. 2-3 cm WLE & FU for 5y (3 monthly for 3y & 6 monthly for 2y).

Stage IIA Breslow ≥ 1–2 mm with ulceration or 2–4 mm with no ulceration.

Stage IIB Breslow 2–4 mm with ulceration or > 4 mm with no ulceration (MM > 4mm has >50% risk of local and distant metastasis & need >3cm excision margins).

Stage IIC Breslow > 4 mm, with ulceration.



Stage IIIA any Breslow thickness with no ulceration but micrometastases 1–3 nodes.

Stage IIIB any Breslow thickness with ulceration or with 1–3 palpable metastatic nodes or satellite metastases.

Stage IIIC any Breslow thickness with palpable LN

Stage IV distant metastases

Referral for regional SSMDT for IIB & CT staging for IIIB, Chemo / clinical trials e.g. Ipilimumb (immunomodulatory Ab), Vemurafenib (Ab against BRAF),

Sentinel lymph node biopsy (SLNB) has no therapeutic, but staging value & may be considered with the WLE for MM Breslow 1- 4mm.

Radiotherapy may be considered for large mm or painful spread to bone

Follow-up every 3m for 1y for stage IA & 5 year for IB-IIIA (3m for 3y then 6m for 2y), 10y for IIIB or above + oncology referral / clinical trials

Prognosis: depend mainly of Breslow level, www.melanomaprognosis.org

Primary prevention: avoid solar radiation e.g. SPF for UVA & UVB, hat with a wide rim

Secondary prevention: Self examination, photos of the moles, regular FU for patient at risk, if a suspicious mole GP referral within 2wk (target is to excise it within 62 d).

	BENIGN	MALIGNANT	
A: ASYMMETRY This benign mole is not asymmetrical. If you draw a line through the middle, the two sides will match, meaning it is symmetrical.			If you draw a line through this mole, the two halves will not match, meaning it is asymmetrical, a warning sign for melanoma.
B: BORDER A benign mole has smooth, even borders, unlike a malignant melanoma.			The borders of an early melanoma tend to be uneven. The edges may be scalloped or notched.
C: COLOUR Most benign moles are all one color—often a single shade of brown.			A variety of colours is another warning signal. A number of different shades of brown, tan or black could appear, as well as red, white or blue.
D: DIAMETER Benign moles usually have a smaller diameter than malignant ones.			Melanomas are usually larger in diameter than the size of a pencil eraser (¼ inch or 6mm), but they may sometimes be smaller when first detected.
E: EVOLVING Common, benign moles look the same over time. Be on the alert when a mole starts to evolve or change in any way.			Any change—in size, shape, colour, elevation, or another trait, or any new symptom such as bleeding, itching or crusting—points to danger.

SKINCANCER.ORG










© Waikato District Health Board 2010





Has >50 moles, but one of them is a dark suspicious mole? Ugly duckling





Is it MIS or LMM ? – take a biopsy from the darkest site








http://dermis.net










http://derm.net
























© Jere Mammino, DO

Is it MM?






www.dermatologia.net




http://dermis.net

















Spilus





Becker

Dermatofibroma (DF)







Squamous Cell Carcinoma (SCC) – ? A non-healing skin lesion

Second common skin cancer, account for 16% of all skin cancer cases (BCC 80% & MM 4%).

Present as indurated nodular keratinising, crusted lesion. Its edges usually irregular, opaque yellow-red, or present as a horn-shape, or dome-shape firm-hard raised skin lesion. Its centre may ulcerate, crusted, scabbed or bleed.

Arise from the squamous cells of any epithelium (skin, GUT, trachea).

Has risk of relapse and spread. Metastasis 0.3-3.7%, worse if affect lower lip, ears, eyelid, scalp, chronic wound & recurrent type.

Risk factors: UVL (persistent accumulative, not periodic), Actinic Keratosis (AK), Bowen's disease (BD), chronic skin irritation , ulcer, scar, skin burns, HPV, LS, LP, DLE, leukoplakia, erythema ab igne, radiation, arsenic, genetic disorders e.g. xeroderma pigmentosum, immune suppression

(SCC:BCC ratio is 1:4, but this ratio reverse in immune suppressed patient e.g. renal transplant may need prophylaxis by acitretin).

SCC histological types: well differentiated / moderate differentiated / poorly differentiated

SCC histological subtypes: spindle cell (Spindle cell carcinomas), acantholytic, desmoplastic, verrucous & Keratoacanthoma (low grade)

High risk SCC: poorly diff, acantholytic, spindle cell, desmoplastic, perineural, lymphatic, or vascular invasion, depth > 4mm, size >2cm, on lip, ear, scalp & on non-sun exposed area or in area of previous injury, transplant patient, if arise from area of radiation, thermal injury, chronic sinus, ulcer, inflammation or Bowen's disease .

DD: common warts, BCC, AK, BD.

Management: (excision & skin cancer MDT review): excision with 4mm margin if SCC size <2cm & 6mm margin if SCC size >2cm, incomplete excision => recurrence rate 30-40% in 2-5y, especially if deep margin involved.

Mohs (MMS) microsurgery provides precise excision. Without Mohs use orienting sutures in bx to identify residual tumour to histopathologists.

Curettage & Cautery (C&C) & cryotherapy may not provide diagnosis & only used for special cases e.g. well differentiated, small SCC <1cm.

Radiotherapy can cure 90% of SCC & gives best cosmetic results, but for >50y old, SCC near eyes, lips, tip of nose & as palliative or after surgery

Follow-up: MDT decision e.g. 1y for low risk SCC & 2 - 5y for high risk SCC (75% of relapse & metastasis are detected within 2y & 95% within 5y)

For palpable LN consider USS, CT, FNBx & oncology/SSMDT referral.

Retinoids e.g. Acitretin may prevent SCC in immune suppressed patient, but rapid relapse of SCC may occur after its discontinuation.

SCC in situ (SIS)

Bowen's disease: usually in non-sun exposed skin &~ 5% may progress into SCC. DD: psoriasis, BCC, Actinic Keratosis, discoid eczema. Rx as in AK

Bowenoid papulosis: SIS of the genitalia, usually in sexually active patient, present as dark warty lesions & associated with HPV.

Erythroplasia of Queyrat: SIS of glans penis presents as shiny bright red macular or ulcer, common in uncircumcised men.

Arsenical keratosis (mainly in palm & sole).

Genital lichen sclerosus and lichen planus: <5% may evolve into SCC and they need regular FU.






SCSA


Globalskinatlas.com

Bowen's disease



Bowen’s disease



Lichen sclerosus





Actinic Keratosis





- Mostly on sun exposed skin (DNA damage)
- Very common in elderly fair skinned persons
- May regress, persist, or progress to SCC
- Diagnosis: clinical, bx if in doubt
- Rx: topical: 5-Fluorouracil (5-FU) Efudix 5% cream bd for 3-6wk, Imiquimod (Aldara) 5% cream, Picato cream od x 3d. Solaraze gel 3%.
- Cryotherapy (liquid nitrogen), shave biopsy.
















1
2
3


©Dermnet.com















Lichen planus


















© The Color Atlas of Family Medicine







Basal cell carcinoma (BCC), Basalioma, Rodent ulcer

Most common cancer, account for 80% of all skin cancers. In 2010, 247,000 BCCs were treated surgically in the UK, >3m cases/y in USA

Grow very slowly ~ 1mm in 3m & double in size in 6-12m, locally invasive & rarely metastasise <0.1%.

Evolves from the basal epidermis (skin stem cell). Common in Caucasian with Fitzgerald skin type I, II, III, after the age of 40 on the face, back, legs, but uncommon in hands, forearm, feet & rarely affect ear, palm, sole, vermilion of the lips & black people.

Risk factors: UVL, fhx, age, genetic e.g. Gorlin's syndrome, ionizing radiation exposure or arsenic, immunodeficiency .

SCC is directly related to cumulative sun exposure, but BCC is related to episodic (intermittent) sun exposure e.g. sunny holiday.

Clinical types: nodular (60%), superficial (30%), cystic, morphoeic (sclerosing), keratotic, and pigmented.

Diagnosis: nodular BCC has pearly raised edges (on skin stretching), telangiectasia (aorborising BV by dermoscopy), ulcer or depressed centre.

DD of BCC: naevus (pigmented BCC may mimic a naevus or MM), trichilemmoma (benign neoplasm of pilosebaceous follicular epithelium has association with Cowden disease or multiple hamartoma syndrome), angiokeratoma, lymphangioma, cylindroma,.

Dermatoscopy: aorborising BV (like tree branches cross the centre). Pigmented BCC shows leaf or globules like lesion but no pigment network

Histological: shows blue nests of epidermal cells with palisading borders, but palisading may also occur in seborrhoeic wart, trichilemmoma ...

Histological subtypes: nodular, superficial, pigmented, and aggressive types includes: micronodular, infiltrative, morphoeic and basoaquamous BCC (behaves like a high risk SCC with risk of recurrence & metastasis).

Management: Excision with 4mm peripheral margin & >2mm deep margin (or include subcutaneous fat).

Low risk BCC (e.g. superficial <2cm is size) can be treated by 5FU (Efudix) 5% bd or Imiquimod 5%, 5d/wk for 3-6wk, cryotherapy (LN), C&C, Photodynamic therapy (PDT)

High risk BCC: >2cm size, on centre of face, eye, ear, lips, nose, morphoeic, perineural, lymphatic or vascular invasion, nodular BCCs with poorly defined margins or recurrent BCC best treated by wide excision with 6mm margin or by Mohs (MMS) microsurgery.

The overall 5 y cure rate of 99% following Mohs. Incompletely excised bcc may recur in 21-41% over 2-5 years.

Recurrent require wider peripheral surgical margins (5–10 mm) than primary lesions or Mohs.

Radiotherapy: used for patient >50y or for better cosmetic results.

Medical treatment: for large or inoperable BCC by Visomodegib (erivedge) .
















7
10
15



Atopic Dermatitis (AD) (Atopic Eczema)

Atopic person: genetic tendency to have AD, asthma, hay fever (allergic rhinitis), and Ig E mediated immune reaction to certain allergens.
Around 80% of AD patients have high Ig E named as atopic (extrinsic) & 20% have normal Ig E named as non-atopic (intrinsic).
Eczema tend to appear in first & >70% clear by age 12y. Around 1/2 of AD develop asthma & 2/3 of them develop either asthma or rhinitis.

AD prevalence >20% & cost UK economy £465m/y.

Normal skin pH = 5.5 but pH may increase (by using e.g. aqueous cream, soap, heat, air-bourn allergens, food, skin infection, cat, dog, stress) causes increase in protease enzyme activity in skin → damage the desmosomes. In contrast low skin pH inhibits protease activity.

Atopic infant is usually born with normal IgE (intrinsic), and those with low FLG develop facial rash first as facial stratum corneum is thin and damaged easily by high pH e.g. soap, hard water, breast milk, olive oil, occlusive dressing with emollient, baby bubble bath, saliva dripping, nasal leakage, dust mites, Staph (activate protease) → damage desmosomes → break skin barriers → allergens enter the skin → generate IgE → eczema change from intrinsic to extrinsic type.

Aetiology: Like psoriasis, AD has polygenic aetiology (genes & environment triggers). Concordance rate or AD risk in identical twins =72-86% & in non-identical = 21-23% & hereditability more strongly linked to maternal side.
Most genetic defect in AD is in chromosome 1q21, which contain all mutations of AD including Filaggrin (fliament aggregation protien) (FLG).
FLG attaches keratin fibres together & its mutation → poor skin barrier, decrease skin Natural Mosturasing Factor (NMF) & increase trans-epidermal water loss (TEWL) → xerosis (dry skin), increase uptake of allergens, increase risk of inhalant allergens, asthma & food allergy → high IgE more than in non-AD. Around 15% of global AD & 50% of all UK hospitalised AD have FLG mutation. FLG contains multiple proteins & mutation of each protein differ from country to another (Kezic et al 2008).

AD histology: Dermatitis means inflammation of the skin but not necessary eczematous process. AD is characterised by spongiosis (intercellular oedema), in acute phase → widening of intercellular spaces, disruption of desmosomes, formation of microvesicles, lymphocyte infiltration & exocytosis. Acanthosis (thick skin) occurs in chronic eczema.

Atopic Dermatitis

Clinically AD onset after birth, but may delay till 3-6m & usually on face (sparing nose tip & buttock), neck, extensor surface affected first then flexures after 1y & sparing the napkin area (unlike Seborrhoeic dermatitis). In children AD causes rash under ear lobe & nipples.

AD with FLG mutation: has early onset, severe, persistent rash, high IgE (extrinsic type), associated with keratosis pilaris (plugged hair follicules in arms or cheeks → goose bump), palmoplanter hyperlinearity, asthma & rhinitis & ichthyosis vulgaris.

Acute AD: xerosis, scaling (hyperkeratosis), ill defined erythema then vesicle formation & scratching => excoriation, crusting, scaling, weeping (exudation), crust (dried exudate), liability to skin infection (HSV, staph). Scratching skin => white line (unlike dermographsim).

Chronic AD: oedema, scaling, thickening (induration), lichenification, fissuring. Facial flare characterised by Dannie Morgan folds (lower eyelids odema (usually 2nd to allergy to pollen and other allergens) & flexural rash + loss of eye brow due to scratching & rubbin.

AD in Black & Asian children causes de pigmentation, rash on extenser of limbs & follicular rash on dorsum of hands or a pale discoid patches (pityriasis alba) due to inactive melanocytes by eczema inflammation , papular or vesicular type (prurigo).

Main secondary infection in AD are staph, HSV, warts. Impetigo 90% due to staph aureus (PVL staph strain => boils) & 10% due to strep-A. Bullous impetigo always due to staph. Treatment by oral or IV flucloxacillin & nasal bactrban cream tds, & bath od for 10 min. with Dermol lotion or Milton bleach (household bleach = Sodium hypochlorite) 2% =125ml in 100 litres of water (1/2 tub) or one cup in full bath.

HSV infection (eczema herpeticum) may present without blisters as small red group of papules & scalp lesion could cause plaques like psoriasis without blister, particularly in neonate, treatment with IV aciclovir for 3wk then prophylaxis which may continue for >1y.

Dermatitis – phenotypes

1-Seborrhoeic dermatitis (non-itchy) unlike AD, SD child is happy & sleep well. It is dermatitis of seborrhoeic rich areas in neonate affects scalp (crudle cup) at birth & flexures including napkin (napkin psoriasis), but usually self-limited in weeks up to 1y, treated by emollient or coconut oil, +/- dactacort cream & rarely evolve into AD or psoriasis. In adult due to reaction to *Malassezia furfur* (*Pityrosporum ovale)*.

2-Contact dermatitis (CD) (delayed immune reaction) 80% due to irritant dermatitis (e.g. water, soap, bubble bath, powders, rough fabric, cosmetics, food, soap, chemical, polishes, solvents, bleach, disinfectants, insecticides) & 20% due to allergic dermatitis e.g. rubber, nickel, chromates, antibiotics, antiseptics, thimerosal, hair dye (p-phenylenediamine), ammonium, persulfate, toluene-2,5 diamine, rubber shoe, fragrance, preservatives, cosmetics, leather, mobile phone contain nickel, textile contain blue dye, airborne by fragrance (all face affected), asthma plastic inhaler, lip stick & tooth paste may cause contact dermatitis around lips.

3-Venous gravitational or stasis eczema due to chronic venous hypertension => chronic panniculitis & varicose eczema.

4-Asteatotic (eczema craquele) more in elderly who overuse soaps.

5-Pompholyx very itchy periodic blisters may be due to allergy to infection (fungi, scabies) or CD. Blisters joint => painful bullae & don't rupture easily as palm epiderms is thick. Later on rupture => dry out in 2w => painful fissure, treated by K.P. sock & topical steroids.

6-Photodermatitis either photoallergic (e.g. Doxycycline) or photoxic (e.g. psoralin).

7-Discoid (nummular) onset in children affect nipple, but more common in elderly >60y mainly in men & leave hyperpigmatation as dermatitis either activate or deactivate melanocytes.

8-Juvenile planter dermatosis common in atopic children age <14y, affect distal planter side of feet & trigger by excessive sweating.

9-Pityriasis alba associated with Aatopy & regarded as early stage of AD present in dark skinned as slightly scaly pale discoid patches.

10-Mixed of multiple phenotypes.

AD DD: Psoriasis, urticaria, Nodular prurigo (80% of patients have personal or family hx of atopy), Lichen Simplex Chronicus (LSC), fungal infection (ringworm), Fe deficiency, thyroid disease, renal or hepatic failure, bed bugs, Scabies, recurrent viral infections e.g. hand mouth disease, bacterial infections e.g. Staph infection (bullos impetigo & PVL), hyperimmunoglobulin IgE syndrome (Job syndrome), HTLV1 infection (mainly in Caribbean children causes eczema like rash around eyes, back of neck), Wiskott Aldrich syndrome, Severe Combined Immune Deficiency (like WA Syndrome, but child has normal plats), HIV, Ichthyosis , Pityriasis rubra pilaris, Netherton's syndrome, Photodermatoses (Actinic prurigo, Chronic actinic dermatitis may occur in children causes facial & lip rash chilitis), Dermatitis Herpetiformis, Mycosis Fungoides, Acrodermatitis enteropathica (zinc deficincey), vitamin deficiency e.g. Pellagra, Omenn's syndrome (failure to thrive, absent thymus, low IgG & B cell, high IgE, T cell, WBC, eosinophilia, LN, poor immunity, erythroderma, recurrent infections).

Eczema

Emollients at least bd (ointment better than cream) e.g. Hydromol, Epaderm, 50/50 LP/WSP, Comfi Fast wrap suits

Bath od with Dermol cream or Oilatium plus bath oil (not for children)

Topical steroids: For the face rash use HC 1% ointment od or protopic 0.03% - 1% ointment (after age 2y)

For the body rash use potent topical steroids od 3-5 days then moderate or weak steroid od 2weeks & review

After improvement start Protopic 0.03% or 0.1% or Elidel oint. bd (pm/nocte) face, eyelids, skin folds. Maintenance twice weekly

Watch for infection (Impetigo, HSV), food allergy, neglect, comorbidity

Topical treatment

Fingertip unit:
Adult male: one fingertip unit provides 0.5 g
Adult female: one fingertip unit provides 0.4 g
Children of four years approximately 1/3 of adult amount
Infants six months to one year approximately 1/4 of adult amount

Amount of cream used / body part:

- One hand: apply 1 fingertip unit
- One foot: apply 2 fingertip units
- Face & neck: apply 2.5 fingertip units
- One arm: apply 3 fingertip units
- One leg: apply 6 fingertip units
- Trunk, front & back: 14 fingertip units
- Entire body: 40 units (5g for a baby)

Atopic dermatitis – Management 1

AD diagnosis criteria: itchy skin + 3 of following: 1-dry skin, 2-positive fhx of eczema or hay fever, 3-skin creases eczema, 4-flexural eczema & 5-onset < 2y (75% of the cases onset < 6m & 90% of the cases onset <5y & 95% <15y).

Monitor AD severity by: SCORD (scoring atopic dermatitis index), EASI (eczema area & severity index). PGSS (patient oriented eczema measure (POEM), patient Global severity scale), NESS (Nottingham eczema severity scale). Assessment of QoL by: IDQOL & CDLQI.

NICE guideline 2007: Emollients, steroid & antihistamine.

First Take detail hx, offer info, leaflets (Eczema society websites provides support), Nurse Support, disability living allowance (DLA) for severe AD

Avoid triggers: soap & inhalant allergens (e.g. dust mites, moulds, pollen, grass), cat & dogs (but removing pet may not clear AD), extreme temperature, dry air, humidity, house mite (in mattress, stuffed toys & old carpets), olive oil (contain oleic acid which can damage the skin), aqueous cream contains Sodium lauryl sulphate (SLS) which increase skin pH.

Emollient: repair skin barrier, used > bd & immediately after bath, demonstrates emollient application with hair direction (avoid rubbing) to avoid folliculitis (demonstration video (www.itchysneezywheezy.co.uk). Avoid high pH soap e.g. Dove & bubble bath as have & use Dermol cream or lotion for bathing. Use fragrance, Lanolin & SLS-free emollient (e.g. emulsifying ointment, 50:50 liquid paraffin:white soft paraffin, diprobase, aveeno, hydromol, unguentum M, epaderm) > bd (500g/wk for adult & 250g/wk for children. White paraffin is more purified petrolatum than yellow paraffin, or use cetraben, balneum, E45, QV, oilatum plus, diprobath or doublebase. Use cream with nosil to prevent hand contamination.

To reduce itching use Lauromacrogols, Balneum plus, E45 itch relief cream, calmurid, aquadrate, nutraplus + bandage e.g. Clinifast or Tubifast tubular bandages for daily wrapping & wait dressing.

Paste bandages: e.g. Icthammol, Steripaste, Viscopaste bandages & Zipzoc stocking (contains zinc), for generalised rash to prevent scratching, but not for infected eczema & not >2wk.

Emollient steroids ratio should be 10:1 &1 fingertip = cover 2 palms.

Use ointments for acute dry lesion & creams for chronic, face, flexures, wet lesions. Occlusion therapy with crepe bandage for lichenified lesion. Educate on how recognise infection, mainly impetigo & eczema herpeticum.

Bathe od (bd in summer) with Dermol cream to minimise skin allergen. Avoid aqueous cream, olive oil. Avoid concentrated oilatium plus bath oil (can cause irritant dermatitis & vitiligo like hypopigmentation). Bleach bath used in USA, to decrease skin bacteria e.g. milton (2% Na hypochlorite) bath for <10min 2/wk put 250ml in a bath (Huang 2009). Or use Crystacide 1% cream bd/tds.

Wet wraps either using 2 cotton non-loose fitting garments (vest, gloves, legging & socks) (e.g. Tubifast, Comfifast, Skinnies skinwear, Clinifast garment) by soaking the first gown with emollient, dress it to the child skin then cover it with dry gown then normal cloths or use silk garment (skinnies skinwear, dermasilk clothing). Wrap every night for >5d then alternative night then 2/wk till clearances, but stop if skin is infected.

Antihistamines: may help to sleep & reduce pollen allergy, but don't stop eczema or itching as it caused by cytokines release & not by histamine.

First choice: 1-non-sedating: cetirizine 10mg (can be increase in adults to 40mg/d), loratadine 10mg, levocetrizine 5mg, desloratadine 5mg, fexofenadine 120mg. 2-sedative: alimemazine 10mg, chlorphenamine maleate (piriton) 4mg, clemastine 1mg, cyproheptadine HCl 4mg, ketotifen 1mg, promethazine HCl 10mg & hydroxyzine (atarax 10mg pm or 10mg/5ml syrup pm, licenced for children).

Atopic dermatitis – Management 2

Topical steroids used it 1h before emollient with 10:1 emollient: steroids. In acute AD use very potent e.g. dermovate or atrivex, elocon for body rash & HC 1% for face for <5d (not on broken or infected skin or HSV), then switch to moderate steroids (eumovate) for 1-2wk then review

Maintenance 2consective day therapy/wk (weekend therapy): e.g. Betnovate RD (as valerate 0.025%) or Eumovate or Trimovate or Haelan tape (for localised lesions) for < 2w. Always use mild steroids fore face (e.g. Hydrocortesone 1%, Fucidin H, Daktacort, or Canesten HC cream), a 100g tube enough for 1m.

Infected eczema (weeping, pustules, crusts, fever, malaise) take swabs & use oral Abx e.g. flucloxacillin is 1st line Abx as staph accounts for 95% of infection (erythromycin or clarithromycin or clindamycin if penicillin allergy) for 1-2wk an review. Staph with Panton-Valentine leukocidin (PVL) virulence cause recurrent abscess (boils), also treated by oral flucloxacillin or clindamycin + decolonisation skin by *Hibiscrub* liquid (contains chlorhexidine) or Dermal wash + Bactroban (mupirocin) oint for the anterior nares tds. Avoid topical Abx e.g. Fuciden-H or Fucibet >1w, as they this may encourage resistance to Abx. Aciclovir IV (not oral) for urgent Eczema herpeticum.

2nd line treatment of eczema: (or if steroids fail or tachyphylaxis) topical calcineurin inhibitors (TCI), only licensed for eczema as alternative to steroid to prevent skin atrophy mainly face & flexure e.g. Tacrulimus 0.1% bd & for children >2y old, but may cause burning, so use Protoic 0.03% or pimecrulimus (Elidel) 0.1% cream, which is less irritant, and causes less burning. Maintenance twice a week for 3-12 months on the healed eczematous areas to prevent relapse. TCI is safe, but avoid using it outdoor, during skin infection, HSV, immune suppressed, or cancer patient.

3rd line treatment for severe eczema: combination of Steroids, CTI, coal tar, TL01, PUVA & may need admission + oral prednisolone 1-2mg/kg/d (enteric coated tablet) till rash clearness then decrease the dose / add steroid sparing agent e.g. Methotrexate (MTX), Azathioprine, Mycophenolate mofetil (MMF), Cyclosporin (Neoral), Omalizumab (humanised monoclonal anti-IgE) used pat with AD, asthma & chronic urticaria. IV immunoglobulin (IV GLOBULIN), Aeroallergen (TLA) air filter device use for asthma & eczema patients.

Alitretinoin 30mg /d licensed for hand eczema for 12w & stop if no response.

Annual FU & pneumonia & flu vaccines. VZV, HBV, BCG may be given, but if on immune suppressive e.g. CYA, MTX, AZA, avoid live vaccine (MMR, typhoid, yellow), avoid sun exposure without SPF & check Vitamin D level.

Prognosis poor in FLG mutation => early onset of severe AD in infancy, concurrent presence of atopic diseases e.g. asthma & hay fever.

Atopic Dermatitis – Management 3

Treatment failure: poor compliance, poor use of emollients, using weak steroid use (steroid phobia), using high pH washing products, wrong diagnosis (see Diff Diag):

Rule out contact allergens & urticaria commonest allergens nickel, cobalt chloride, neomycin, fragrance mix, caine mix, metal (except 22 gold, aluminium, steal & platinum), detergent, rubber, drugs, hair dye, formaldehyde, concentrated oilatum bath oil => sore dermatitis.

Food Allergy (FA) affects around 8% of children & 2% of adults & it don't cause eczema but aggravate it. Its prevalence ~70% in child <6m old with severe eczema & not responding to topical therapy, but usually disappear by age 16y except peanut & egg allergy may last for life.

Food limitation don't cure eczema but improve it. Main allergens nut, egg, cow milk, sesame, soya, gluten, chicken, fish, oats.

FA types: -

1-Acute FA (IgE mediated) causing urticaria, hives, facial swelling, cough, wheeze within 2 hours of eating food.

Investigations: high IgE level confirms type-1 hypersensitivity to an allergen, but not AD & not always associated with food allergy, rhinitis, asthma. Specific IgE/total IgE ratio may help to diagnose the allergen in food. Mast cell beta-trypase released by mast cell with histamine & increases at anaphylaxis & urticaria, so we do its baseline test at time of urticaria & at 2-3h after onset of allergy. Prick test, but +ve test don't necessary mean FA & –ve test don't exclude FA. Rradioallergosorbent test (RAST) has low specificity / PPV & high sensitivity / NPV i.e. +ve test means sensitisation to an allergen, but not necessary allergic to that allergen, while -ve RAST may not 100% rule out allergy to the allergen. Also +ve test doesn't identify which allergen epitope (e.g. in peanut) the patient is sensitive to & what type of cross reaction to another allergens the pat have & what is the severity of allergic reaction the patient will have if he was give the allergen. Therefore we use a new ImmunoCAP ISAC Microarry test to detect which epitope in peanut the patient sensitive to, before conducting challenging test (gold standard). Treatment by avoiding allergens + EpiPen (150 for infant <15kg, 300 for adolescent >30kg & 500 for adult >60kg). Desensitisation may be offered in a specialised centre and under dietician supervision. For infant < 6m old try hydrolysed formulas e.g. Neocate milk for 8wk (with a dietician growth chart monitoring). For older children they may tolerate small amount e.g. baked or cooked milk.

2-Chronic FA (non-IgE mediated) onset >2h - 3d e.g. abdominal cramps, refuse food, crying, gastric reflex (acidic & non-acidic), diarrhoea, blood with stool, delay growth chart, lactose allergy may be 2 to GIT infection. Wheat (gluten) allergy is not always associated with Coelaic.

3-Mixed type.





20%, Filaggrin, NMF















IV








© Jere Mammino, DO

3-5%, *M,* P, H










DermNetNZ.org






© R Suhonen




SCIENCEphotoLIBRARY



























Psoriasis

- **Prevalence 1-3% but long life morbidity**
- **Types: type-I < 40y familial & HLA Cw6 +ve 5-9y in girls & 15-19y in boys**
  type-II > 40y sporadic & HLA Cw6-ve

- **Phenotypes: plaque (vulgaris) 90%; guttate; flexural (inverse); generalised putular (von Zumbusch); Palmoplanter pustulosis psoriasis (PPPP); erythrodermic, nail psoriasis, Psoriatic Arthritis (PsA).**

- **Aetiology: Genetic: PSORS1-9 & PSORS1 (and its loci HLA-Cw6), accounting up to 50% of genetic susceptibility (Nestle et al, 2009).**

- **Environment: trauma (Koebner Phenomenon), stress, drugs (b blocker, ACEI, IF- a, systemic steroids, lithium), infection (strep-A), smoking, alcohol, UVL, immunodeficiency, AIDS.**

- **IMD unknown stimulus activates dendritic cells => stimulate Th1 & Th17** (Davidovici et al, 2010)

- **Th1 => TNF-a, IF-g, IL-2, IL-12 => release of infl cells & epidermal growth factor => proliferation of keratinocytes in 4d (28d)**

- **Th17 activation => IL-22 => keratinocytes proliferation in 4d instead of 28d.**







Plaque Psoriasis (vulgaris)































Differential Diagnosis










© EFPIA










Walking
Gentlemen






DermNetNZ.org


Walking
Gentlemen









Management

Diagnosis: clinical, Fhx, bx.

Differential Diagnosis: AD, LP, PRP, PLC, fungal, MF, BD.

Treatment: No cure

1-Topical: emollients, Vitamin D analogue, Steroids, Dithranol, Coal tar

2-UVL: UVB-TL01 (maximum 350 visits) or PUVA (maximum 200 visits)

3-Systemic: Methoteroxate, Acitretin, Neoral, Fumaderm, Biologics

Skin biopsy









Psoriasis Comorbiditis

1-Physical / personal (Eghlileb et al, 2007)

2-Psychological (Schmitt & Ford, 2010) (Han 2011)

3-Cardiovascular diseases (CVD) (Mehta, 2010)

4-Metabolic Syndrome (MS) (Langan 2012)

5-Psoriatic Arthritis (PsA) up to 40% affected

Physical disability

Scaly flaky itching rash, soreness or burning sensation, occasionally bleeding stain clothes / bed sheets

&

Dystrophic nail changes can interfere with daily activities embarrassment at work /public places (de Berker, 2009).

Psychological disability

- Skin is a major organ of social & sexual communication in all races. Psoriasis chronic unpleasant visible rash effects on self-image, self-esteem and emotional stability (Magin et al, 2009; Uhlenhake et al, 2009).

- Depression found to be present even in mild psoriasis cases affecting small parts of BSA and can lead to poor compliance and treatment outcomes (Hayes & Koo 2010).

- Depression in psoriasis often under diagnosed or undertreated by physicians in primary care (Mitchell et al, 2009) & secondary care (Richards et al, 2004).

Cumulative life course impairment

- The physical, psychological and metabolic comorbidities associated with psoriasis can prevent patients from attaining their life goals, pursuing their desired educational level or chosen career (Warren et al, 2011).

Economic loss

- In the USA, the total direct and indirect costs for psoriasis patients are calculated at $11.25 billion annually, excluding patient out of pocket costs or loss of productivity at work (Fowler et al, 2008). Additionally, although the cost of treating psoriasis patients usually correlates with the severity of the disease (Fowler et al, 2008), the disease is associated with widespread treatment dissatisfaction and carries a substantial burden even when not extensive (Stern et al, 2004)

- The failure of managing psoriasis & its comorbidities would be more costly to the health service than if such comorbidities were prevented at an early stage (Stern et al, 2004; Horn et al, 2007).

Thank you